Patent 9604960 was granted and assigned to ALBANY MOLECULAR RESEARCH, INC. on March, 2017 by the United States Patent and Trademark Office.
Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.